Bendamustine as Part of Conditioning Regimen for Autologous Stem-Cell Transplantation in Patients With Aggressive Lymphomas: Final Analysis of a Phase 2 Study From Geltamo

Hematological Oncology - United Kingdom
doi 10.1002/hon.2438_54
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Autologous Stem Cell Transplantation as Part of First-Line Therapy in Patients With Peripheral T-Cell Lymphoma: A Multicenter Geltamo/Fil Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Mitoxantrone-Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed/Refractory Lymphoma

Turkish Journal of Medical Sciences
Medicine
2019English

Retrospective Analysis Leam Conditioning for Autologous Stem Cell Transplantation

Biology of Blood and Marrow Transplantation
TransplantationHematology
2018English

Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (With Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial

Biology of Blood and Marrow Transplantation
TransplantationHematology
2017English

Thiotepa/Cyclophosphamide/Tbi as a Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome

Bone Marrow Transplantation
TransplantationHematology
2004English

High-Dose Therapy With Autologous Stem Cell Transplantation in Patients With Peripheral T Cell Lymphomas

Bone Marrow Transplantation
TransplantationHematology
2001English

A Reduced-Intensity Conditioning Regimen for Patients With Dyskeratosis Congenita Undergoing Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation
TransplantationHematology
2016English

Impact of Conditioning Regimen on Outcomes for Patients With Lymphoma Undergoing High-Dose Therapy With Autologous Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation
TransplantationHematology
2015English

Results of a Prospective Phase II Trial With Ofatumumab as Part of Reduced Intensity Conditioning Regimen in High-Risk Non-Hodgkin B Lymphoma Patients: A GELTAMO Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy